Evidence map›Paper›PMID 41315409›Full record

Observational studyScientific reports2025

Associations between systemic inflammation and cognitive trajectories post-stroke.

Heidi Vihovde Sandvig, Ingvild Saltvedt, Trine Holt Edwin, Stina Aam, Katinka Nordheim Alme, Rannveig Sakshaug Eldholm, Stian Lydersen, Tom Eirik Mollnes, Ragnhild Munthe-Kaas, Per Magne Ueland and 3 more

Registry-linked trialAbstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02650531 (Norwegian COgnitive Impairment After STroke), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02650531 completednot on this map

Norwegian COgnitive Impairment After STroke (NorCOAST) Study

TypeobservationalSponsorNorwegian University of Science and TechnologyRan2015 to 2018Enrolled816ConditionsDementia, Mild Cognitive Impairment, Stroke
3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Heidi Vihovde SandvigDepartment of Medicine, Kristiansund Hospital, Sjukehuset Nordmøre og Romsdal, Møre og Romsdal Hospital Trust, Kristiansund, Norway. Heidi.V.Sandvig@ntnu.no.ORCID http://orcid.org/0000-0002-0591-8377
Ingvild SaltvedtDepartment of Neuromedicine and Movement Science, Faculty of Medicine and Health Sciences, NTNU - Norwegian University of Science and Technology, Trondheim, Norway.
Trine Holt EdwinDepartment of Geriatric Medicine, Oslo University Hospital, Ullevaal, Oslo, Norway.
Stina AamDepartment of Neuromedicine and Movement Science, Faculty of Medicine and Health Sciences, NTNU - Norwegian University of Science and Technology, Trondheim, Norway.
Katinka Nordheim AlmeDepartment of Internal Medicine, Haraldsplass Deaconess Hospital, Bergen, Norway.
Rannveig Sakshaug EldholmDepartment of Neuromedicine and Movement Science, Faculty of Medicine and Health Sciences, NTNU - Norwegian University of Science and Technology, Trondheim, Norway.
Stian LydersenDepartment of Mental Health, Faculty of Medicine and Health Sciences, NTNU - Norwegian University of Science and Technology, Trondheim, Norway.
Tom Eirik MollnesDepartment of Immunology, Oslo University Hospital and University of Oslo, Oslo, Norway.
Ragnhild Munthe-KaasDepartment of Medicine, Kongsberg Hospital, Vestre Viken Hospital Trust, Drammen, Norway.
Per Magne UelandBevital A/S, Laboratoriebygget, Bergen, 5021, Norway.
Arve UlvikBevital A/S, Laboratoriebygget, Bergen, 5021, Norway.
Torgeir WethalDepartment of Stroke, Clinic of Medicine, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.
Anne-Brita KnapskogDepartment of Geriatric Medicine, Oslo University Hospital, Ullevaal, Oslo, Norway.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Our objective was to explore whether plasma inflammatory biomarkers and related metabolites in acute phase and 3 months after stroke were associated with different cognitive trajectories and with changes in cognition post-stroke. The Norwegian Cognitive Impairment After Stroke (Nor-COAST) study was a prospective, multicentre cohort study of patients with acute stroke, followed up at 3, 18, and 36 months post-stroke. First, we modelled cognitive trajectory groups based on Montreal Cognitive Assessment (MoCA) scores and used multinominal logistic regression to study the associations between systemic inflammatory biomarkers/metabolites and group membership. Second, using mixed linear regression, we investigated whether the same biomarkers/metabolites were associated with changes in MoCA scores over time, stratified by pre-stroke cognitive status. The 466 participants had mean (SD) age 72 (12) years, 59% were males, and mean (SD) NIHSS score at admittance was 4 (4.8). Higher acute-phase values of the terminal complement complex, interleukin 6, macrophage inflammatory protein 1α, neopterin, quinolinic acid, and PA ratio = 4-pyridoxic acid / (pyridoxal + pyridoxal 5'-phosphate) and higher 3-month values of neopterin were associated with increased risk of being in the group characterized by low and declining MoCA score compared to the group of best MoCA score (p < 0.01). Higher acute-phase values of tumour necrosis factor and interleukin 8, were associated with progressive decline in the MoCA score (p < 0.01). Premorbid factors, and in particular pre-stroke frailty, had more impact on the models than stroke-related factors, and partly confounded several of these associations. Higher degrees of systemic inflammation in the acute phase were associated with worse cognitive trajectories and may reflect the response to the acute stroke, stroke-related complications and/or premorbid conditions.Trial registration: ClinicalTrials.gov: NCT02650531. Retrospectively registered January 8, 2016. First participant included May 18, 2015.

Indexed as

CognitionCognitive DysfunctionInflammationStrokeAgedAged, 80 and overBiomarkersFemaleHumansMaleMiddle AgedNorwayProspective StudiesBiomarkersCognitive trajectoriesFrailtyIschemic strokeSystemic inflammationThe terminal C5b-9 complement complexTumour necrosis factor

Identifiers

PMID41315409
PMCPMC12663362

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.